DRUG · Unmapped registry intervention
FG-3246
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
FG-3246DRUG
Sponsors & collaborators
Kyntra Biolead sponsor
Mapped research locations
Los AngelesCalifornia, United States2SeattleWashington, United States2HoustonTexas, United States1DallasTexas, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1ClevelandOhio, United States1DurhamNorth Carolina, United States1New HavenConnecticut, United States1TucsonArizona, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06842498 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.